Pacira Pharmaceuticals (PCRX) Shares are Up 8.73%

Pacira Pharmaceuticals (PCRX) : Traders are bullish on Pacira Pharmaceuticals (PCRX) as it has outperformed the S&P 500 by a wide margin of 2.04% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 8.16%, relative to the S&P 500. The stock has risen by 8.73% in the past week indicating that the buyers are active at lower levels, but the stock is down -0.02% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 3.86% and the 50-Day Moving Average is 6.04%.The 200 Day SMA reached 18.26% Pacira Pharmaceuticals, Inc. is up 9.66% in the last 3-month period. Year-to-Date the stock performance stands at -44.88%.


Pacira Pharmaceuticals (PCRX) : Currently there are 7 street experts covering Pacira Pharmaceuticals (PCRX) stock. The most bullish and bearish price target for the stock is $109 and $47 respectively for the short term. The average price target of all the analysts comes to $75.57. The estimated standard deviation from the target is $18.98.

For the current week, the company shares have a recommendation consensus of Buy. Pacira Pharmaceuticals (NASDAQ:PCRX): The stock opened at $40.65 and touched an intraday high of $42.499 on Friday. During the day, the stock corrected to an intraday low of $40.17, however, the bulls stepped in and pushed the price higher to close in the green at $42.33 with a gain of 4.42% for the day. The total traded volume for the day was 1,055,901. The stock had closed at $42.33 in the previous trading session.

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the companys lead product candidate, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Companys other product candidates include DepoMeloxicam and DepoTranexamic Acid.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.